Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
Boehringer Ingelheim
Johnson and Johnson
AstraZeneca
Harvard Business School

Last Updated: December 6, 2022

CLINICAL TRIALS PROFILE FOR DUAVEE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Duavee

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02100553 ↗ Study Evaluating Effects of Multiple-Dose Administration of Itraconazole on the Single Dose Pharmacokinetics of Conjugated Estrogens/Bazedoxifene in Non-Obese and Obese Postmenopausal Women Completed Pfizer Phase 1 2014-04-01 This study will assess if itraconazole will affect the blood levels of Duavee when they are given together. This study will also assess if a subject's body size affects the blood levels of Duavee.
NCT02237079 ↗ Bazedoxifene/Conjugated Estrogens (BZA/CE) Improvement of Metabolism (BIM) Completed Tulane University Health Sciences Center Phase 4 2014-12-01 The goal of this pilot clinical study is to perform a randomized placebo-controlled study to assess the beneficial effect of a 3 month-treatment with Bazedoxifene/Conjugated Estrogens (BZA/CE) vs. placebo on glucose homeostasis and body composition in 20 post-menopausal women. The recruitment will be performed at Tulane Health Sciences Center.
NCT02274571 ↗ Raising Insulin Sensitivity in Post Menopause Completed Pennington Biomedical Research Center Early Phase 1 2015-09-01 The purpose of this study is to find out if a novel drug approved by the Food and Drug Administration [Duavee™, Pfizer, Inc] for treatment of postmenopausal symptoms (vaginal dryness and hot flashes) and prevention of osteoporosis also improves insulin sensitivity by decreasing body fat especially in your liver. DUAVEE™ (Conjugated Estrogens/Bazedoxifene) is a new prescription medicine that contains a mixture of estrogen (the main female hormone made by the ovaries) and bazedoxifene, which is FDA approved. For over 60 years, estrogens have been used as hormonal treatments to help manage hot flashes and help prevent postmenopausal bone loss. But in the treatment of postmenopausal women, the use of estrogens alone can increase the risk of developing cancer of the uterus. So estrogens have been traditionally paired with a progestin to decrease the risk of hyperplasia (the thickening of the lining of the uterus), which can be a precursor to cancer. DUAVEE™ uses bazedoxifene, a selective estrogen receptor modulator (SERM), in place of a progestin to help protect the uterus against thickening of the uterus that may result from estrogens alone. In this study, you will get either DUAVEE™ or the placebo (a "dummy pill" that may look like medicine but contains no active medication) first and then switch to the other pill.
NCT02694809 ↗ The PROMISE Study: Duavee in Women With DCIS Recruiting National Cancer Institute (NCI) Phase 2 2017-01-01 The main purpose of this study is to determine if taking the study drug, conjugated estrogens/bazedoxifene (Duavee®) causes any changes in the proliferation markers within the breast tissue of the study subjects. The study drug is approved by the US Food and Drug Administration in healthy postmenopausal women to treat certain symptoms of menopause such as hot flashes. Since it is not approved in women with DCIS, its use in this study is experimental. This study will also look at whether taking the study drug causes any significant or undesirable side effects in women with DCIS. The researchers hope that this study will help them determine if taking the study drug is safe in women taking DCIS and if it can possibly reduce the risk of developing breast cancer in women with DCIS.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Duavee

Condition Name

Condition Name for Duavee
Intervention Trials
Menopause 3
Obesity 2
Breast Cancer 2
Multiple Sclerosis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Duavee
Intervention Trials
Breast Neoplasms 5
Multiple Sclerosis 1
Prediabetic State 1
Breast Carcinoma In Situ 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Duavee

Trials by Country

Trials by Country for Duavee
Location Trials
United States 20
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Duavee
Location Trials
California 3
Louisiana 3
Illinois 2
Kansas 2
Massachusetts 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Duavee

Clinical Trial Phase

Clinical Trial Phase for Duavee
Clinical Trial Phase Trials
Phase 4 3
Phase 2 5
Phase 1 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Duavee
Clinical Trial Phase Trials
Completed 4
Not yet recruiting 4
Terminated 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Duavee

Sponsor Name

Sponsor Name for Duavee
Sponsor Trials
Pfizer 3
Carol Fabian, MD 2
National Cancer Institute (NCI) 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Duavee
Sponsor Trials
Other 16
Industry 3
NIH 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
Harvard Business School
Baxter
Johnson and Johnson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.